Interleukin 2 low dose - Beijing ShuangLu Pharmaceutical/Peking University

Drug Profile

Interleukin 2 low dose - Beijing ShuangLu Pharmaceutical/Peking University

Alternative Names: hrIL-2; Recombinant human IL-2

Latest Information Update: 17 Nov 2015

Price : $50

At a glance

  • Originator Beijing ShuangLu Pharmaceutical; Peking University
  • Developer Beijing ShuangLu Pharmaceutical; Monash University; Peking University
  • Class Adjuvants; Antineoplastics; Interleukins; Lymphokines
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Sjogren's syndrome; Systemic lupus erythematosus

Most Recent Events

  • 29 Sep 2015 Efficacy and pharmacodynamics data from a phase II trial in Systemic lupus erythematosus released by Peking University
  • 01 Jun 2015 Phase-II clinical trials in Sjogren's syndrome in China (SC) (NCT02464319)
  • 01 Jun 2015 Phase-II clinical trials in Systemic lupus erythematosus in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top